器官移植术后HCV感染诊疗规范(2019版)

中华医学会器官移植学分会

doi:10.3969/j.issn.1001-5256.2019.10.008

器官移植术后HCV感染诊疗规范(2019版)

DOI: 10.3969/j.issn.1001-5256.2019.10.008

中华医学会器官移植学分会

基金项目:

国家自然科学基金(81570680,81571555)；

详细信息

中图分类号: R617;R512.63
计量
- 文章访问数: 177
- HTML全文浏览量: 4
- PDF下载量: 115
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-26
- 出版日期: 2019-10-20

Diagnosis and treatment standard for hepatitis C virus infection after organ transplantation(2019 edition)

Chinese Society of Organ Transplantation, Chinese Medical Association

Research funding:

摘要

摘要: 为了进一步规范实体器官移植(SOT)术后HCV感染的诊断和治疗,中华医学会器官移植学分会组织器官移植专家和感染病学专家,从流行病学、SOT术后HCV感染的诊断、SOT术后HCV感染的预防和治疗等方面,制订本规范,以帮助器官移植工作者规范和优化HCV感染的诊断和治疗。
- 器官移植 /
- 肝炎病毒 /
- 感染 /
- 诊疗准则(主题)
Abstract: In order to further standardize the diagnosis and treatment of hepatitis C virus(HCV) infection after solid organ transplantation(SOT),Chinese Society of Organ Transplantation,Chinese Medical Association,organizes the experts in organ transplantation and infectious diseases to formulate this standard from the aspects of epidemiology and the diagnosis,prevention,and treatment of HCV infection after SOT,so as to standardize and optimize the diagnosis and treatment of HCV infection among the medical staff involved in organ transplantation.
- organ transplantation /
- hepacivirus /
- infection /
- practice guidelines as topic

HTML全文

参考文献(22)

[1] LANINI S,PISAPIA R,CAPOBIANCHI MR,et al. Global epidemiology of viral hepatitis and national needs for complete control[J]. Expert Rev Anti Infect Ther,2018,16(8):625-639.

[2] SUN YY,LIU HX,WANG N. Hepatitis C virus genotypes in China:A systematic review[J]. Chin J Epidemiol,2013,34(1):80-84.(in Chinese)苏迎盈,刘慧鑫,汪宁.中国丙型肝炎病毒基因型分布[J].中华流行病学杂志,2013,34(1):80-84.

[3] WONG MCS,HUANG JLW,GEORGE J,et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J].Nat Rev Gastroenterol Hepatol,2019,16(1):57-73.

[4] CHEN YS,LI L,CUI FQ,et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol,2011,32(9):888-891.(in Chinese)陈园生,李黎,崔富强,等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志,2011,32(9):888-891.

[5] COILLY A,ROCHE B,SAMUEL D. Current management and perspectives for HCV recurrence after liver transplantation[J].Liver Int,2013,33(Suppl 1):56-62.

[6] DOMNGUEZ-GIL B,MORALES JM. Transplantation in the patient with hepatitis C[J]. Transpl Int,2009,22(12):1117-1131.

[7] FORMAN LM,LEWIS JD,BERLIN JA,et al. The association between hepatitis C infection and survival after orthotopic liver transplantation[J]. Gastroenterology,2002,122(4):889-896.

[8] HEIDRICH B,PISCHKE S,HELFRITZ FA,et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients[J]. J Viral Hepat,2014,21(11):769-779.

[9] ALONSO R,PREZ-GARCA F,LPEZ-ROA P,et al. HCV core-antigen assay as an alternative to HCV RNA quantification:A correlation study for the assessment of HCV viremia[J]. Enferm Infecc Microbiol Clin,2018,36(3):175-178.

[10] FABRIZI F,AGHEMO A,MESSA P. Hepatitis C treatment in patients with kidney disease[J]. Kidney Int,2013,84(5):874-879.

[11] BURRA P,RODRGUEZ-CASTRO KI,MARCHINI F,et al.Hepatitis C virus infection in end-stage renal disease and kidney transplantation[J]. Transpl Int,2014,27(9):877-891.

[12] Kidney Disease:Improving Global Outcomes(KDIGO). KDIGO clinical practice guidelines for the prevention,diagnosis,evaluation,and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl,2008(109):s1-s99.

[13] CIESEK S,PROSKE V,OTTO B,et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation[J]. Transpl Infect Dis,2016,18(3):326-332.

[14] TERRAULT NA,STOCK PG. Management of hepatitis C in kidney transplant patients:On the cusp of change[J]. Am J Transplant,2014,14(9):1955-1957.

[15] LIN MV,SISE ME,PAVLAKIS M,et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLo S One,2016,11(7):e0158431.

[16] KIEFFER TL,SARRAZIN C,MILLER JS,et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients[J].Hepatology,2007,46(3):631-639.

[17] FABRIZI F,MARTIN P,MESSA P. New treatment for hepatitis C in chronic kidney disease,dialysis,and transplant[J]. Kidney Int,2016,89(5):988-994.

[18] MORALES JM,FABRIZI F. Hepatitis C and its impact on renal transplantation[J]. Nat Rev Nephrol,2015,11(3):172-182.

[19] Kidney Disease:Improving Global Outcomes(KDIGO)Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention,diagnosis,evaluation,and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl,2018,8(3):91-165.

[20] XUE W,PAN D,YANG Y,et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K,A156V and D168A to TMC435[J]. Antiviral Res,2012,93(1):126-137.

[21] WALKER A,FILKE S,LBKE N,et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure[J]. Virol J,2017,14(1):106.

[22] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[R]. Geneva:World Health Organization,2018:1-83.

施引文献

资源附件(0)

访问统计